KPTI

Karyopharm Therapeutics Inc. Q4 Loss Misses Estimates

(RTTNews) - Karyopharm Therapeutics Inc. (KPTI) reported Loss for fourth quarter that missed the Street estimates.

The company's bottom line came in at -$41.837 million, or -$0.36 per share. This compares with -$38.506 million, or -$0.43 per share, in last year's fourth quarter.

Analysts on average had expected the company to earn -$0.31 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter rose 0.5% to $33.747 million from $33.580 million last year.

For the full year, Karyopharm Therapeutics Inc. (KPTI) expects total revenue of $140 million to $160 million, in line with analysts' estimate of $152.02 million. Research and development, and SG&A expenses are projected to be in the range of $260 million to $280 million, which includes around $20 million to $25 million of estimated non-cash stock-based compensation expense.

Karyopharm Therapeutics Inc. earnings at a glance (GAAP) :

-Earnings (Q4): -$41.837 Mln. vs. -$38.506 Mln. last year. -EPS (Q4): -$0.36 vs. -$0.43 last year. -Revenue (Q4): $33.747 Mln vs. $33.580 Mln last year.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.